New Trump Administration, New Republican Congress - Webinar CD/Transcript

$287.00
Quantity Discounts
1 - 2
$287.00
3 - 4
$258.00
5 - 6
$244.00
7 - 9
$230.00
10 - 9999
$215.00

New Trump Administration, New Republican Congress: What Will the FDA’s Agenda Be in 2017?

The US has a new president, a new Congress, and almost assuredly a new agenda for the FDA — with different policies and priorities than the current administration.

What does this mean for FDA regulated industries?

Steve Grossmann — a long-time D.C. insider, who served as a Senate Health Committee Staff Director and Deputy Assistant Secretary of Health — will discuss what the FDA is  doing today and what it likely will be doing under the next administration.

After attending this session you will learn:

  • The likelihood that the current commissioner will continue to head the agency —for how long — and who the top candidates are to replace him
  • Who will head the FDA transition team and how the process will likely unfold in the next months
  • What the FDA’s likely priorities will be in 2017 under the new administration besides the medical device tax and drug pricing and the signals you need to watch for to determine how the new policies will likely impact your company — and your job on a daily basis
  • How the new Congress is likely to impact what FDA does in 2017 and whether there will be increased monitoring of specific FDA projects, offices and policies

Order today for a glimpse of what 2017 will bring for the FDA and its regulated industries.

Anyone in a position to lead an FDA-regulated company, develops a new product for regulatory approval, or is concerned about trends in FDA regulation and policy will benefit from this webinar.

Steven Grossman, President, HPS Group, LLC
Steven Grossman is President of HPS Group, LLC, a consultancy that provides strategic counsel, analysis and advocacy on regulatory and policy issues involving the U.S. Food and Drug Administration.  Mr. Grossman serves on the Board of Directors of the National Organization for Rare Disorders (NORD) and sits on the board’s executive committee. He is also a founder and deputy executive director of the Alliance for a Stronger FDA, a multi-stakeholder coalition that advocates for increased resources for the FDA. Earlier in his career, Mr. Grossman was Deputy Assistant Secretary for Health at HHS and Health Staff Director and Counsel to the Senate HELP Committee.